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The epidermal growth factor receptor 2 (HER2) is a tyrosine kinase overexpressed in nearly 20% to 25% of invasive breast
cancers. Trastuzumab is a humanized monoclonal antibody that targets HER2. The majority of patients with metastatic breast
cancer initially respond to trastuzumab, however, within 1 year of treatment disease progresses. Several molecular mechanisms
have been described as contributing to the development of trastuzumab resistance. They could be grouped as impaired access of
trastuzumab to HER2, upregulation of HER2 downstream signaling pathways, signaling of alternative pathways, and impaired
immune antitumor mechanisms. However, since many of them have overlapping eﬀects, it would be of great clinical impact to
identify the principal signaling pathways involved in drug resistance. Signiﬁcant eﬀorts are being applied to ﬁnd other therapeutic
modalities besides trastuzumab treatment to be used alone or in combination with current modalities.
1.Introduction
Breast cancer is the most common malignancy worldwide
and the second leading cause of cancer death in women in
USA and the ﬁrst one in Argentina [1]. In the past decades,
the development of strategies for breast cancer treatment
focused on understanding the expression, regulation, and
function of critical signaling pathways involved in cancer
initiation and progression and allowed the identiﬁcation of
breast cancer subsets with diﬀerent biology [2]. One of the
most important targeted therapies has been the use of the
antihuman epidermal growth factor receptor 2 (HER2) for
tumors overexpressing this receptor [3].
Breast cancer is a heterogeneous disease that can be
classiﬁed in diﬀerent subsets with distinct biology and mole-
cular proﬁles [4], some of which can be associated with en-
hanced tumor aggressiveness and poor clinical outcome [5].
Breast tumors vary according to the expression of estro-
gen receptor (ER), progesterone receptor (PR), and ampli-
ﬁcation of HER2 which is overexpressed in approximately
20% to 25% of invasive breast cancers [6]. The resulting
subgroups are important not only for clinical behaviour
and prognosis, but also for predictive response to targeted
therapies against these receptors and the pathways they
activate.
The HER2/neu gene encodes a 185-kDA transmembrane
tyrosine kinase (TK) receptor that belongs to the EGF
receptor (EGFR) family which consists of EGFR/ErbB1
(HER1), ErbB2 (HER2), ErbB3 (HER3), and ErbB4 (HER4).
All receptors, with the exception of HER3, contain a
cytoplasmatic TK region and all, with the exception of
HER2, bind speciﬁc ligands via extracellular domains.
Upon ligand binding, receptors dimerize using HER2 as
their preferential binding partner [6]. These receptors are
expressed in a variety of tissues of epithelial, mesenchymal,
and neuronal origin [7]. Activation of the HER receptors
under physiological conditions is controlled by spatial and
temporal expression of their ligands, members of the EGF
family of growth factors. Homo- or heterodimerization of
receptors after ligand binding results in the phosphorylation
of residues from the intracellular domain of the receptor,
resulting in the recruitment of signaling molecules from the
cytoplasm and the initiation of several signaling pathways.
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to enhanced cell motility, survival, and proliferation as
well as resistance to apoptosis [8]. Certain pathways are
preferentially modulated by diﬀerent receptors due to the
ability of each receptor to bind speciﬁc eﬀector proteins. Two
of the main activated pathways are RAS/Raf/MAPK and the
phosphatidylinositol 3-kinase (PI3K)–Akt pathways [9].
Overexpression of HER2 enables constitutive activation
of growth factor signaling pathways, serving as oncogenic
drivers in breast cancer. It is well known that cancer patients
whose tumors have alterations in HER receptors tend to have
amoreaggressivediseaseassociatedwithpredictivefactorsof
a poor clinical outcome [10]. Constitutive EGFR activation
canbeelicitedbyEGF-relatedgrowthfactorsproducedeither
by the tumor cells themselves or by the surrounding stromal
cells [11].
2. HER2 as Target for Cancer Therapy
Ampliﬁcation of HER2 was originally detected in a subset of
breast tumours [12]a sw e l la si ng a s t r i c[ 13], ovarian [14],
and salivary gland cancers [15]. Concerning breast cancer
treatment, HER2 has features that allow it to be considered
as an ideal therapeutic target, since their levels strongly
correlate with tumorigenesis, as demonstrated by gain [16]
a n dl o s so ff u n c t i o n[ 17], gene overexpression in metastatic
breast cancers [12], and its association with poor disease-
free survival [18]. Overexpression (25-fold increase in HER2
gene copy numbers) is found in nearly 30% of breast cancer
[19] either in primary tumors as well as in metastatic sites,
indicating that anti-HER2 therapy would be an eﬀective
approach for all disease sites. Hence, targeting HER2 protein
could reduce the pathogenicity caused by tumor cells [20].
Two important types of HER2 inhibitors are currently
in clinical use: humanized antibodies directed against
EGFR/ErbB2 and small-molecule tyrosine-kinase inhibitors
(TKIs)thatcompetewithATPinthetyrosine-kinasedomain
of the receptor. In preclinical models, both inhibitors rapidly
downregulate PI3-AKT, MAPK, SRC, and STAT signaling,
consequently blocking the proliferation of tumour cells and
h u m a nx e n o g r a f t si nn u d em i c e[ 21, 22].
Antibody-based therapy targeting HER2 is based on
the development of monoclonal antibodies (mAbs) against
epitopes present in the HER2 extracellular domain. Upon
bindingtotheircognateepitopes,theseantibodiesexerttheir
antitumor eﬀects by multiple mechanisms.
Trastuzumab (Herceptin, Genentech Inc., San Francisco
Calif, USA) is a humanized recombinant mAb that binds to
the extracellular domain of the human HER2 protein [23].
Currently, it is the only HER2-targeted therapy approved by
the FDA for metastatic breast cancer treatment. It selectively
exerts the antitumor eﬀects in experimental animals and
patients with HER2-ampliﬁed breast tumors but not in
tumors with normal HER2 expression [24, 25]. However, the
clinical eﬃcacy of trastuzumab is limited, since a signiﬁcant
number of patients with HER2 overexpressing tumors will
be initially or eventually resistant to trastuzumab [26]. An
overall response rate (complete + partial responses) rang-
ing from 15% to 30% has been obtained when used as
singleagent;however,higherresponserates(50%–80%)have
been reported when used in combination with standard
chemotherapy for metastatic disease [27–29].
Understanding the mechanisms of resistance to trastuz-
umab is, therefore, crucial for the development of new thera-
peutic strategies [7].
3. Mechanismsof TrastuzumabAction
Although trastuzumab is currently widely used for the treat-
ment of HER2-overexpressing breast cancer, its mechanism
of action is not fully understood [30].
3.1. Eﬀect on Cell Cycle. Trastuzumab binds to HER2 with
high aﬃnity, inducing a cytostatic eﬀect associated with
G1 arrest, reduction in cell proliferation, and apoptosis
via upregulation of the cyclin-dependent kinase inhibitor
p27kip1 [31]. It has been demonstrated by Western blot and
by immunoprecipitation that breast tumor cell lines treat-
ed in vitro with trastuzumab increased p27kip1 levels and
interaction with CDK2, resulting in a decrease in CDK2
activity [32].
3.2. Eﬀect on the PI3K Pathway. HER2 and EGFR activate
signaling through PI3K/Akt pathway. When PI3K becomes
activated, it generates phosphoinositides which cause AKT
translocation to the plasma membrane, where it phospho-
rylates and becomes able to phosphorylate diﬀerent targets.
On the other hand, AKT can be negatively regulated by
antagonizingtheactionofthephosphataseandtensinhomo-
logue (PTEN) on PI3K. Trastuzumab can possible reduce
the signaling by this pathway, promoting arrest of cell pro-
liferation and apoptosis [33].
3.3. Inhibition of HER2 Extracellular Domain Proteolysis.
Overexpressed HER2 undergoes proteolytic cleavage, releas-
ing the extracellular domain which generates a truncated
membrane-bound fragment (p95) found in serum patients
[34]. Molina et al. [35] demonstrated that trastuzumab
inhibited HER2 cleavage and thus the shedding of the
extracellular domain, possibly by the inhibition of metallo-
proteinases activity. Indeed, the authors detected a phos-
phorylated truncated receptor in almost half of the human
breast cancer serum samples. A decrease in serum HER2
extracellular domain upon trastuzumab treatment could be
considered as predictor of host response [36], since it was
associated with improved progression-free survival.
3.4. Inhibition of Angiogenesis. Trastuzumab modulates the
eﬀects of diﬀerent pro- and anti-angiogenic factors as well as
normalization and regression of the vasculature in a xeno-
graft model of human HER2-overexpressing breast tumor. A
reduction of VEGF production only in vitro has been des-
cribed, indicating that in vivo, the eﬀect of trastuzumab is
VEGF-independent [37]. A decrease in microvessel density
in vivo has also been observed [38]. Expression of proangio-
genicfactorswasreduced,whileexpressionofantiangiogenicInternational Journal of Breast Cancer 3
factors was increased in trastuzumab treated tumor-bearing
a n i m a l sv e r s u sc o n t r o l s .
3.5. Internalization and Degradation of HER2 Protein.
Another mechanism of trastuzumab eﬀect can be due to
downregulation of HER2 through endocytosis; clinical data
conﬁrming this pathway is conﬂicting. Hommelgaard et al.
[39] using the breast cancer cell line SKBR3 described the
preferential association of HER2 with the plasma mem-
braneprotrusions,makingHER2aninternalization-resistant
receptor. Cuello et al. [40], using the same tumor cell line,
reported that trastuzumab downregulated HER2 protein.
The formation of large lattices between antibodies and
antigens at cell surface, collapsing into the cytoplasm and
being degraded in lysosomes has been proposed [41]. In
thiscase,internalizationanddegradationwouldbeincreased
by the concomitant use of antibodies targeting diﬀerent
epitopes on HER2, as shown by Portera et al. [42].
3.6. Immune-Mediated Response. Data from in vivo exper-
iments and clinical trials indicate that the eﬃcacy of
trastuzumab could be partially related to its induction of
an immune response. In vivo breast cancer models and
clinical trials have demonstrated that trastuzumab has not
only cytostatic but also cytotoxic properties, at least in part
via antibody-dependent cellular cytotoxicity (ADCC). This
immunological eﬀect has been observed in vitro with a
variety of breast cancer cell lines [43]. Stockmeyer et al. [44]
demonstrated that apoptosis and ADCC against the breast
cancer cell line SKBR3 treated with bispeciﬁc anti-HER2
mAb only happened when neutrophils were present.
It is known that ADCC is mainly due to natural killer
cells (NK) that, when activated, express the Fcγ receptor that
binds the Fc domain of the IgG1 trastuzumab. In a xenograft
model, activated NK could lyse tumor cells associated with a
tumour regression rate of 96%. In mice lacking the Fc re-
ceptor, only 29% tumour growth inhibition was observed
[44]. These results led to the conclusion that an active
immune response to trastuzumab may be responsible for the
antitumor activity. Gennari et al. [45] selected 11 patients
withHER2-positivebreasttumoursreceivingtrastuzumabat
a standard dose before breast surgery. Trastuzumab treated
patients who showed complete or partial remission were
found to have a higher in situ inﬁltration of leukocytes and
a higher capability to mediate in vitro ADCC. However, they
could not detect changes in total HER2 levels or downstream
signalings such as alterations in cell proliferation or tumor
vasculature. It is necessary to continue studying the partici-
pation of ADCC in mediating the response to trastuzumab.
3.7. Inhibition of DNA Repair. Pietras et al. [46]o b s e r v e d
that trastuzumab partially inhibited DNA adducts repair in-
duced by cisplatin and that it also blocked DNA synthesis
after radiation in in vitro studies [47].
4. Mechanismsof TrastuzumabResistance
It should be noted that most of the mechanisms of trast-
uzumab resistance have been identiﬁed in preclinical models
and have not been completely validated in clinical samples.
One important goal is to clarify which of all the mechanisms
are clinically relevant. However, it is known that, as with
other drugs, clinical resistance will be multifactorial. [7, 30,
48].
Themostrelevantmechanismsoftrastuzumabresistance
in breast cancer are shown in Figure 1.
5.ImpairedTrastuzumabBindingtoHER2
5.1. Truncated HER2. Diﬀerent metalloproteases cleave the
extracellular domain of HER2, creating a truncated receptor
to which trastuzumab is unable to bind [49]. Thus, the
membrane-bound portion, remains as a truncated constitu-
tively active HER2 receptor with kinase activity but lacking
theextracellulardomaintobindtrastuzumab[50].However,
in vitro data suggested that trastuzumab could block the
cleavage of HER2 and consequently the production of
constitutively active p95HER2 [35]. A retrospective clinical
study revealed a strong association between the presence of
p95HER2 and patients resistance to trastuzumab treatment
[50]. Extracellular domain HER2 level has been evaluated
as potential predictor for treatment response in metastatic
breastcancerbuthadlowpredictivevaluesforclinicalbeneﬁt
with trastuzumab therapy [51]. According node status and
HER2 expression, Molina et al. [49] reported that the
expression of p95 HER2 was more frequent in node-positive
cases compared to node-negative ones.
5.2. Masking with MUC 4 and CD44/Hyaluronan Polymer
Complex. Epitope masking has also been described as a
mechanism of resistance to trastuzumab. Mucin 4 (MUC4)
is membrane-associated glycoprotein [52], which consists
of several highly glycosylated proteins that form protective
barriers on epithelial cells including mammary epithelium.
In this sense, MUC4 can contribute to cancer progression
due to its ability to inhibit recognition of cancer cells by the
immune system, promoting tumor progression, metastasis,
and suppression of apoptosis [53, 54]. MUC4 may interfere
with trastuzumab binding by masking HER2 receptor [55,
56]. In a preclinical study with the human HER2-positive
trastuzumab-resistant JIMT-1 cell line, expression of MUC4
was associated with decreased antibody-binding capacity,
being able to reverse resistance using RNA interference to
knockdown MUC4 [56].
AnotherHER2maskingthatblockstrastuzumabbinding
is mediated by CD44, a transmembrane receptor for hya-
luronan. It has been shown that binding of polymeric
hyaluronan, activates CD44-mediated signaling pathways
including RAS and PI3K [57]. Binding of endogenous
hyaluronan polymer to CD44 contributes to PI3K/Akt acti-
vation [58]. Blocking CD44- hyaluronan polymer binding
by the use of anti-CD44 antibodies or hyaluronan oligomers
suppressed the PI3K/Akt signaling pathway, inhibiting
anchorage-independent tumor cell growth.4 International Journal of Breast Cancer
Gene expression
(a) Truncated HER2 (a) Epitope masking
SOS
SHC
(c) Increased signaling
from other receptors
(c) Increased signaling
from HER family
receptors
(b) Increased PI3K/Akt
signaling
Alternative
signaling
pathway
(d) Impaired immune-
mediated mechanisms
(b) PTEN loss
PI3K
PTEN
PDK1
Akt
mTor
ERKs
Raf
Ras
G
R
B
2
H
E
R
1
H
E
R
2
HER2
VEGF
I G FR1
HER3
HER3
HER3
MEK 1/2
(b) PDK1
changes
Figure 1:Relevantmechanismsoftrastuzumabresistanceinbreastcancer:(a)ImpairedtrastuzumabbindingtoHER2:truncatedHER2and
epitope masking. (b) Upregulation of HER2 downstream signaling pathways: PTEN loss, increased PI3K/Akt activity and PDK1 changes. (c)
Alternative signaling pathways: Increased signaling from HER family and other receptors. (d) Impaired immune-mediated mechanisms.
6. Upregulation of HER2Downstream
SignalingPathways
6.1. PTEN Loss. T h el o s so ff u n c t i o no fP T E N( p h o s p h a t a s e
and tensin homolog) caused by mutation, or by transcrip-
tional regulation, has been described in several tumors
including nearly 50% of breast cancers [59]. PTEN nor-
mally inhibits the activation of PI3K; therefore, PTEN loss
results in constitutive activation of PI3K/Akt [60]. Decreased
expressionoractivityofPTENblockedtrastuzumab-mediat-
ed growth inhibition in HER2 overexpressing breast cancer
cells [61]. Nagata et al. [33] have emphasized the im-
portant role of decreased expression of PTEN protein
resulting in an increase in PI3K/Akt phosphorylation and
signaling, preventing trastuzumab-mediated growth arrest
of HER2-overexpressing breast cancer cells. Patients with
PTEN-deﬁcient HER2-overexpressing metastatic breast can-
cer had signiﬁcantly worse responses to trastuzumab than
those with normal PTEN tumors [33, 59]. Berns et al.
[62], using a large-scale RNA interference screen, identi-
ﬁed PTEN as the only gene whose knockdown resulted
in trastuzumab resistance.
In clinical trials, Dave et al. [63] conﬁrmed that low
PTENoractivatingmutationinPIK3CAconferredresistance
to trastuzumab regimen, whereas low PTEN tumors were
associated with a high pathologic complete response. Acti-
vation of PI3K pathway was associated with trastuzumab
resistance, whereas low PTEN predicted for response to lapa-
tinib. These observations support clinical trials with the
combination of both agents.
6.2. Increased PI3K/Akt Activity. PI3K mutations are also
involved in trastuzumab resistance through PI3K/Akt path-
way activation. The PIK3R1 gene encodes the PI3K reg-
ulatory subunit p85α,a ﬀecting its function and inducing
constitutive activation of the PI3K/Akt pathway [64, 65].
In addition, PIK3CA (activator of the same pathway and
frequently mutated in breast cancer) is the gene that encodes
the catalytic subunit of p100α of PI3K. It is frequently
mutated or overexpressed in human cancer [66] and is able
to confer resistance to trastuzumab in cell culture [66]. In
a clinical study using 55 patients with breast cancer, Berns
et al. [62] described signiﬁcantly improved ability to detectInternational Journal of Breast Cancer 5
patients with low response to trastuzumab when combining
the analysis of low PTEN expression with the presence of
oncogenic PIK3CA mutations. They also described an asso-
ciation of PIK3CA hotspot mutations and reduced time to
progression after therapy.
Junttila et al. [67] showed that trastuzumab disrupts
ligand-independent ErbB2/ErbB3/PI3K complexes blocking
AKT signaling; when PI3K is mutated, complex disruption
does not inhibit AKT, explaining why trastuzumab is ineﬀec-
tive in some tumors. Recent studies using HER2-ampliﬁed
breast cancer cell lines showed that those cell lines with
PIK3CA hotspot mutations were signiﬁcantly more resistant
to trastuzumab than those without mutations [68]. Thus,
assessment of PI3K pathway activation might be considered
a biomarker to identify patients unlikely to respond to tra-
stuzumab-based therapy. An activating mutation of Akt1
situated in the pleckstrin homology domain (E17K) was
identiﬁed in breast cancer and occurs early in the develop-
ment of the disease [69]. However, this mutation has not
been identiﬁed in HER2-overexpressing tumors [70].
6.3. PDK1 Changes. Overexpression of PDK1 was found in
approximately 20% of breast cancers [71]. Tseng et al. [72]
in a preclinical model reported that the combined use of
PDK-inhibitors with trastuzumab reversed the trastuzumab-
resistant phenotype of SKBR3 human breast cancer cells.
6.4. Modulation of p27Kip1. Another mechanism of trastuzu-
mab resistance is dependent of the cyclin-dependent kinase
inhibitor p27kip1 [73]. Several studies have suggested that
p27kip1 is a critical element of trastuzumab response and that
itsdownregulationcanpromotetrastuzumabresistance[74].
The growth inhibitory properties of trastuzumab depend, in
part, upon the eﬀects on the cyclin-dependent kinase-inhi-
biting protein p27kip1 [75]. Treatment with cyclin-dependent
kinase 2 (CDK2) inhibitors led to a dramatic decrease in cell
proliferation and enhanced apoptosis [76]. In vivo, CDK2
inhibition signiﬁcantly reduced tumor growth of trastuzu-
mab-resistant xenografts. They suggested that the use of
CDK2 inhibitors in patients with breast tumors with HER2
and cyclin E coampliﬁcation/overexpression might be a valid
strategy. Le et al. [77] have also suggested that any drugs or
therapies that directly aﬀects p27kip1 or its signaling would
inﬂuence the eﬃcacy of trastuzumab. Actions on more than
one target or pathways may have synergistic or additive eﬀect
against overexpressing HER tumor cells.
7.AlternativeSignalingPathways
Signaling through multiple alternative pathways has been
linked to trastuzumab resistance in various preclinical mod-
els.
7.1. Increased Signaling from HER Family Receptors. Com-
pensatory crosstalk occurs among receptors within the
HER family [78–80]. Although trastuzumab reduces HER2-
mediated signaling, it might not reduce signaling from other
HER receptors. HER1/HER3 heterodimers or HER1/HER1
homodimers expressing cells might initiate MAPK and PI3K
signaling even in the presence of trastuzumab [21, 78].
HER3 is the favored receptor for dimerization with
HER2 [81], and growing evidence supports HER3 as be-
ing a required partner in HER2-overexpressing breast cancer
[82, 83]. The oligomerization properties of the HER recep-
tors conﬁrmed that interactions between EGFR/HER2 and
HER2/HER3 are detected in the presence of ligand. In ad-
dition, they found that trastuzumab is ineﬀective in blocking
HER2/HER3 dimerization [84].
Transforming growth factor α (TGF α) is a ligand of the
HER family, and it is involved in the formation of HER2
heterodimers. In vitro, trastuzumab was less eﬃcient in inhi-
biting cell growth in presence of TGF α [85]. In addition,
increased levels of the HER family ligands such as heregulin
and EGF blocked trastuzumab-mediated growth inhibition
in HER2 overexpressing breast cancer cell lines [86].
7.2. Increased Signaling from Other Receptors
7.2.1. Insulin-Like Growth Factor-1 Receptor Overexpression.
The insulin-like growth factor-1 receptor (IGF-1R) is a
transmembrane TK receptor frequently expressed in human
breast cancers. Its downstream eﬀectors promote prolifer-
ation and metastatic dissemination [30]. HER-2 and the
IGF-1R share common postreceptor signaling pathways. Cell
proliferation is also stimulated by IGF-1R which interacts
with HER2 in trastuzumab-resistant cell lines. The ﬁrst
research article that focused on molecular mechanisms
contributing to trastuzumab resistance described IGF1R
signaling as the contributing cause of resistance [87]. The
authors demonstrated that trastuzumab-mediated growth
inhibition was lost in breast cancer cells that overexpressed
both HER2 and IGF1R. Preclinical studies have implicated
IGF-1R-signaling in resistance to trastuzumab and anti-IGF-
1R drugs restored sensitivity in resistant cells [88]. IGF-
1R-mediated resistance to trastuzumab seems to involve the
PI3K/Akt pathway, leading to enhanced degradation of p27
[48, 89]. It can be suggested that coexpressing HER2 and
IGF-1R tumorsaremore likelytobe resistanttotrastuzumab
therapy.
7.2.2. Vascular Endothelial Growth Factor Overexpression.
Increase in tumor angiogenesis in breast tumors is associ-
ated with overexpression of HER2 [90]. Mice treated with
trastuzumab induce normalisation and regression of the
vasculature in a xenograft model of HER2-overexpressing
breast tumour. Izumi et al. [37], however, observed a re-
duction in vascular endothelial growth factor (VEGF) pro-
duction by cancer cells only in vitro, indicating that a VEGF-
independent antiangiogenic mechanism might act in vivo.
This mechanism appears to be due to the modulation of dif-
ferent regulators of the complex machinery of angiogenesis.
7.2.3. c-Met Coexpression. The c-Met receptor, another TK
receptor, can be coexpressed with HER2 in cell lines
contributing to trastuzumab resistance through sustained
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respond to trastuzumab with a rapid upregulation of c-Met
receptor expression and activation protecting cells against
trastuzumab [91]. Loss of c-Met function by RNA interfer-
enceimprovestheresponseofthesecelllinestotrastuzumab.
Met-ampliﬁcation, and certain alternative signals from Met
to HER3 have been found capable of inducing acquired
resistance to the EGFR TKIs geﬁtinib and erlotinib in non-
small cell lung cancer [92].
7.2.4. Hormone Receptor Signaling. A potential mechanism
of resistance is through ER (it says estrogen receptor) path-
way.TheexistenceofapotentialcrosstalkbetweenHER2and
this pathway has been widely described [93–95]. Up-regu-
lation of the estrogen receptor after treatment with lapatinib
(anti-HER2 mAb) suggests that the receptor might act as a
redundant survival pathway [96].
Crosstalk between the steroid hormone receptors for
ER and progesterone (PR) and the HER family appears to
be a hallmark of breast cancer growth. Proietti et al. [97]
highlighted signal transducer and activator of transcription
3 (Stat3) as a key protein activated by heregulin (HRG),
a ligand of the HER receptors through co-opted ligand-
independent PR function as a signaling molecule. Stat3 acti-
vation was an absolute requirement in HRG-induced mam-
mary tumor growth, and targeting Stat3 eﬀectively inhibited
growth of breast cancer cells with activated HRG/HER2 and
PR. A novel potential therapeutic intervention in PR- and
HER2-positive breast tumors involving the speciﬁc blockage
of PR signaling activity could be investigated.
Other hormones such as prolactin acting through Janus
kinase activation can transactivate HER2, leading to cell
proliferation even in the presence of trastuzumab [98].
7.2.5. Cyclin E Ampliﬁcation/Overexpression. The clinical
relevance of cyclin E ampliﬁcation/overexpression detected
in numerous HER2 breast cancer patients has been report-
ed [76], resulting in a lower clinical beneﬁt rate and
progression-free survival after trastuzumab therapy. High
cyclin E expression has been proposed as a marker of poor
clinical outcome in breast cancer [99]. Furthermore, it has
been recently shown that cyclin E levels decrease upon HER2
downregulation, suggesting that HER2 regulates cyclin E
function [100] .T h er o l eo fc y c l i nEi nt r a s t u z u m a br e -
sistancesuggeststhattreatmentwithCDKinhibitorsisapro-
bable approach for patients whose tumors display cyclin E
ampliﬁcation/overexpression.
7.2.6. Tumor Necrosis Factor α Transactivation. Rivas et al.
[101] have shown that tumor necrosis α (TNFα) induces
HER2 phosphorylation in breast cancer cells, which is
mediated by c-Src activation. Moreover, TNFα promoted
HER2/HER3 heterocomplex formation, Akt activation, and
NF-κB transcriptional activation. Inhibition of HER2 by
addition of AG825, an EGFR/HER2-tyrosine kinase in-
hibitor,orknockdownofHER2byRNAinterferenceblocked
TNFα-induced NFkB activation and cell proliferation. How-
ever, trastuzumab could not inhibit TNFα ability to promote
breast cancer growth. Interestingly, TNFα is able to transac-
tivate HER2 and use it as a mandatory downstream signaling
moleculeinthegenerationofmitogenicsignals.AsTNFαhas
been shown to be present in the tumor microenvironment of
a signiﬁcant proportion of human inﬁltrating breast cancers,
it would have clinical implication in HER2-positive breast
cancer treatment.
7.2.7. Erythropoietin Coexpression. Erythropoietin (EPO)
has long been known to be an important hematopoietic
cytokine that regulates the survival, proliferation and diﬀer-
entiation of the erythroid progenitor cells in the bone mar-
row [102]. EPO-induced cell signaling via interaction with
speciﬁctyrosine-phosphorylatedregionswithintheactivated
receptor for erythropoietin (EpoR), leads to activation of
downstream signaling pathways, such as the MEK/Erk and
PI3K/Aktpathways[103].Thesedownstreamsignalingpath-
ways activated by EPO via EpoR overlap and/or interact with
those activated by HER2.
Recently,Liangetal.[104]demonstratedthattheEpoRis
coexpressed with HER2 in a signiﬁcant percentage of human
breast tumor specimens and breast cancer cell lines. Expo-
sure of these dual-positive breast cancer cells to recombinant
human erythropoietin (rHuEPO), activated cell signaling.
Concurrent cell treatment with rHuEPO and trastuzumab
reduced the cell responsiveness to trastuzumab both in vitro
and in vivo. They identiﬁed Jak2-mediated activation of
Src and inactivation of PTEN as underlying mechanisms
through which rHuEPO antagonizes trastuzumab-induced
therapeutic eﬀects.
7.2.8. Contribution of Rac1 Activity. Rac1, a Ras-like small
GTPase, has been implicated in the control of cell growth
and morphology and is believed to be associated with
breast cancer progression. Dokmanovic et al. [105] using
SKBR3 cells have reported that resistance to trastuzumab
was associated with increased Rac1 activity, leading to
signiﬁcant cytoskeleton disorganization. Redution of Rac1
activity with a speciﬁc inhibitor, restored trastuzumab-me-
diated endocytic downregulation of HER2 and reduced
extracellular signaling regulate kinase activity in resistant
clones. In addition, the role of Rho GTPases as a treatment
target has been recently reviewed by Menna et al. [106].
These results highlight Rac1 as a potential therapeutic target
for the treatment of trastuzumab-resistant breast cancer.
8.ImpairedImmune-MediatedMechanisms
Breast tumor cells isolated from in vitro resistance to trastu-
zumab remain sensitive to trastuzumab antitumor eﬀects in
vivo and to ADCC killing. Tumor cells resistant to trastuzu-
mab in vitro, remain sensitive to its antitumor eﬀect in
vivo as well as to antibody dependant cellular cytotoxic-
ity (ADCC) killing [107]. Gene polymorphism producing
the phenotype expression of valine (V) or phenylalanine
(F) at amino acid 158 on the FcγRIIIa modiﬁes the aﬃnity
of IgG1 to the Fcγ receptor [108]. Immune eﬀector cells
carrying the FcγRIIIa V/V alleles mediate a stronger ADCCInternational Journal of Breast Cancer 7
of trastuzumab than cells bearing the F allele [109]. In the
clinic, the FcγRIII 158V/F polymorphism interferes with
the ability to generate in vitro ADCC responses during tra-
stuzumab treatment, impairing the clinical response and
progression-free survival of patients in the metastatic setting
[110]. Further evidence on the importance of ADCC was
providedbyBaroketal.[111],whoshowedthattrastuzumab
can trigger ADCC and destroy trastuzumab-resistant HER2
positive cell lines in vitro and in vivo xenografts.
In summary, these observations point to ADCC as a
m a j o rp l a y e ri nt r a s t u z u m a ba n t i t u m o r a le ﬀect. It would be
very interesting to know how ADCC aﬀects cells that are
pronetoenhancePI3K/AktandRAS/Raf/MAPKpathwaysin
order to survive. Multiple proteases involved with infection,
inﬂammation, and tumor environments are able to cleave
IgG molecules on site, generating monovalent or bivalent
antibodyfragments,Fab orF(ab)2,whichlackFc-mediated
eﬀector function [112]. However, these antibody fragments
can still bind to their cognate antigen, but lack binding sites
for complement and for Fc receptors, and can no longer trig-
ger Fc-mediated functions such as ADCC.
In our laboratory, we are studying the mechanisms
involved in trastuzumab eﬀect and resistance in diﬀerent hu-
man breast cancer cells overexpressing HER2. Our study is
mainy focused using 3D cultures of tumor cells (spheroids)
in presence or not of syngeneic macrophages or peripheral
mononuclear cells [113, 114].
9. Conclusion
Trastuzumabisanexampleoftargetedtherapythatoﬀerssig-
niﬁcantclinicalbeneﬁtinpatientswithHER2overexpressing
cancers in the adjuvant and metastatic settings. However,
nearly 70% of patients, who initially reasonable option tra-
stuzumab, demonstrate disease progression within 1 year
of treatment. Elucidation of the mechanisms involved in
de novo and acquired resistance to trastuzumab seem to
be diﬃcult due to the multiple mechanisms of action. A
strategy to overcome resistance may involve the use of
treatments that do not depend on molecular binding to
the HER2 extracellular domain, including the use of TK
inhibitors such as lapatinib or of inhibitors of the down-
stream HER2 signaling pathways. Another reasonable option
would be to increase tumor cell destruction through extra-
cellular mechanisms by increasing or enabling ADCC or by
using immunotoxins such as the antibody-drug conjugate
trastuzumab-DM1 [115] or the bispeciﬁc anti-HER2/CD3
Ab ertumaxomab.
Based on emerging knowledge of the HER2-signaling
pathways and of signaling through alternative pathways,
severaldrugsagainstHER2-overexpressingbreastcancersare
in diﬀerent phases of clinical development, whereas others
are still struggling to leave the bench.
It will be of great clinical impact to discover and identify
potential molecular predictors of response to current and
new HER2-targeted agents. Understanding the mechanisms
b yw h i c hH E R 2c a nb ea c t i v a t e db yn o n c l a s s i c a lr e c e p t o r s
and ligands is relevant in order not only to design new ther-
apeutic approaches, but also to predict patient’s response.
Many new agents are currently in preclinical stages of
development. They include HER2 targeting agents as mAbs,
TKIs, and vaccines. Pertuzumab, a recombinant humanized
HER mAb that blocks dimerization of HER2 with HER3 and
EGFR [116], is one of the new classes of drugs called di-
merization inhibitors. It has the potential to block signaling
by other HER family receptors as well as inhibiting signaling
in cells that express normal levels of HER.
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